## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.8% below STRENGTH zone (3.0-6.0%); PEG 2.23 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($133.10)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Agilent Technologies (A) price target increased by 10.53% to 170.51**
- Source: MSN | 20251216T030736 | Bullish | Relevance: 100%
- The price target for Agilent Technologies (A) has been increased by 10.53%, bringing it to $170.51. This adjustment reflects new analyst projections for the company's valuation.

**2. Liontrust Investment Partners LLP Has $95.53 Million Position in Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251214T114217 | Somewhat-Bullish | Relevance: 100%
- Liontrust Investment Partners LLP reported a reduction of 5.4% in their Agilent Technologies (NYSE:A) holdings, now owning 811,207 shares valued at $95.53 million. This comes as company insiders, including the VP and CEO, have sold a combined 16,401 shares worth approximately $2.47 million in the last 90 days. Despite the institutional selling and insider transactions, Agilent Technologies recently beat Q3 earnings estimates, increased its quarterly dividend, and received a "Moderate Buy" consensus rating from analysts with an average price target of $161.77.

**3. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Raises Stock Position in Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251213T103111 | Bullish | Relevance: 100%
- BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its stake in Agilent Technologies (NYSE:A) by 29.2% in the second quarter, bringing its total holdings to 467,657 shares valued at $55.19 million. Other institutional investors also adjusted their positions, and Wall Street analysts have issued "buy" and "overweight" ratings with price targets up to $185.00. The company also announced a quarterly dividend increase.

**4. Agilent to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: Barchart.com | 20251216T133306 | Neutral | Relevance: 100%
- Agilent Technologies Inc. announced that CEO Padraig McDonnell and CFO Adam Elinoff will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, 2026, from 9 to 9:40 a.m. PST. A live audio webcast and replay will be available on Agilentâ€™s Investor Relations website. Agilent Technologies is a global leader in analytical and clinical laboratory technologies, with fiscal year 2025 revenue of $6.95 billion and approximately 18,000 employees worldwide.

**5. Agilent Technologies (A) Receives Analyst Rating Upgrade by Barc**
- Source: GuruFocus | 20251215T145448 | Bullish | Relevance: 100%
- Barclays has upgraded Agilent Technologies (A) from Equal-Weight to Overweight, maintaining a price target of $165.00 USD. This upgrade reflects increased confidence in Agilent's future market performance, following reports of other firms like Goldman Sachs and Morgan Stanley initiating coverage with positive ratings. Agilent, a life science and diagnostic firm, serves various end markets, with Wall Street analysts forecasting an average target price of $167.33, implying an upside from its current price.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $165 | $165 | 0% |
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | up | Overweight |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.23 elevated, pricing in significant growth expectations. Forward P/E 21.4x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $39.9B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.23 |
| Forward P/E | 21.4 |
| Current P/E | 23.6 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -6.4% to -0.8% (+5.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.8pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.9%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-1.38), momentum weakening. RSI neutral at 41. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.78% (CS: 20) | Neutral |
| RSI_14 | 40.6 | Neutral |
| MACD Histogram | -1.38 | Bearish |
| vs SMA20 | 0.957x | Below |
| vs SMA50 | 0.968x | Below |
| vs SMA200 | 1.132x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $140.60
- **Stop Loss:** $133.10 (5.3% risk)
- **Target:** $148.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 160
- **Position Value:** $22,496.00
- **Portfolio %:** 22.50%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*